

# Pharmaceutical Needs Assessment

Health and Wellbeing Board

8 October 2014

---

Author: Acting Director of Public Health

Wards: All

Locality Affected: All

Parishes Affected: All

---

## 1. Purpose and Reasons

- 1.1 The Health and Wellbeing Board (HWB) has a statutory responsibility to prepare a Pharmaceutical Needs Assessment (PNA) for Swindon and publish it by 1<sup>st</sup> April 2015. This report presents information regarding the background and purpose, governance, consultation requirements and overview of proposed contents and timescales.
- 1.2 The purpose of the PNA is to:
  - 1.2.1 Identify the pharmaceutical services currently available and assess the need for pharmaceutical services now and in the future;
  - 1.2.2 Inform the planning and commissioning of pharmacy services by identifying which services should be commissioned for local people, within available resources, and where these services should be;
  - 1.2.3 Inform decision making in response to applications made to NHS England by pharmacists and dispensing doctors to provide new pharmaceutical services, including new pharmacies, and also to make changes to existing contracts. The organisation that will make these decisions is NHS England.

## 2. Recommendations

The Board is recommended to:

- 2.1 Note this report.
- 2.2 Delegate authority to the Acting Director of Public Health to respond, on behalf of the Board, to neighbouring Health and Wellbeing Board's Pharmaceutical Needs Assessments consultations.

## 3. Detail

- 3.1 The Health and Social Care Act 2012 established Health and Wellbeing Boards. The Act also transferred responsibility to develop and update Pharmaceutical Needs Assessments from Primary Care Trusts (PCTs) to HWBs with the requirement to have a new PNA published by 1<sup>st</sup> April 2015.

# Pharmaceutical Needs Assessment

Health and Wellbeing Board

8 October 2014

---

- 3.2 Swindon's existing 2011 PNA will be retained until the updated PNA is produced by the Health and Wellbeing Board. The new PNA will need to be signed-off by the Health and Wellbeing Board by the end of March 2015.
- 3.3 The PNA is a legal document which details services which would be desirable and essential in a locality based on the local health needs and population demographics. The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 set out the legislative basis for developing and updating PNAs and can be found at: <https://www.gov.uk/government/news/new-pharmaceutical-services-regulations-published>.
- 3.4 PNAs will inform commissioning decisions by local authorities (public health services from community pharmacies) and Clinical Commissioning Groups (CCGs). NHS England area teams will also use the PNA to inform whether a pharmacy application would be desirable for a particular location or to make changes to existing pharmacy contracts.
- 3.5 The development of the Swindon PNA process is monitored through the established Joint Strategic Needs Assessment (JSNA) Steering Group and led by public health.
- 3.6 The Swindon PNA is subject to a 60 day statutory consultation period which will start in November 2014. Regulation 8 of the Pharmaceutical Services Regulations specifies that the Health and Wellbeing Board must consult with the following:
- the Local Pharmaceutical Committee (LPC)
  - the Local Medical Committee (LMC)
  - any persons on the pharmaceutical lists and any dispensing doctors list for its area
  - any LPS chemist in its area with whom NHS England has made arrangements for the provision of any local pharmaceutical services
  - Healthwatch, and any other patient, consumer or community group in its area which in the view of the Health and Wellbeing Board has an interest in the provision of pharmaceutical services in its area
  - any NHS trust or NHS foundation trust in its area
  - NHS England
  - any neighbouring HWB
- 3.7 The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 which set out the legislative basis for developing and updating
- 

Further information on the subject of this report can be obtained from Cherry Jones, 01739 444681, [cherryjones@swindon.gov.uk](mailto:cherryjones@swindon.gov.uk).

# Pharmaceutical Needs Assessment

Health and Wellbeing Board

8 October 2014

---

PNAs also provides guidance on content and this has been reflected in the overview of proposed content of the PNA.

- 3.8 The Swindon HWB neighbouring HWBs are Wiltshire, Gloucestershire, Oxfordshire and Berkshire. These HWBs will approach the Swindon HWB as part of their consultation process and Swindon, in turn, will approach them. It is proposed that the Board delegate authority to the Acting Director of Public Health to respond, on behalf of the Board, to the neighbouring HWB PNAs consultations. A checklist of issues Public Health will consider when responding to other HWB consultations will include:

- 3.8.1 Does the neighbouring area provide pharmaceutical services (pharmacy or dispensing GP) to a significant number of Swindon residents?
- 3.8.2 If so, are these adequate in terms of number, opening hours and services offered? Have these been noted in the PNA?
- 3.8.3 Do a significant number of residents from the neighbouring area use Swindon pharmaceutical services? If so, what is the impact?
- 3.8.4 Are there plans for significant house building or other relevant developments close to the Swindon boundary? What impact may these have in the future?
- 3.8.5 Has the neighbouring PNA identified any gaps in provision that are relevant to Swindon?

## 4. Alternative Options

- 4.1 No alternative options are proposed.

## 5. Implications

### Financial and Procurement Implications

- 5.1 There are no financial or procurement implications arising from this report. The actual PNA that this report refers to, when published in April 2015, will inform commissioning decisions by NHS England, SBC public health and NHS Swindon Clinical Commissioning Group.

### Legal and Human Rights Implications

- 5.2 There are no direct legal or human rights implications arising from this report. The PNA will be subject to a diversity impact assessment.

### All other Implications

- 5.3 None.

# Pharmaceutical Needs Assessment

Health and Wellbeing Board

8 October 2014

---

## **6. Consultees**

- 6.1 The Board Director – Finance, Revenues, Benefits and Property (Section 151 Officer) and Director of Law and Democratic Services (Monitoring Officer) are consulted in respect of all reports.

## **7. Background Papers**

- 7.1 None.

## **8. Appendices**

- 8.1 None.